The Iron Chelator Dp44mT Causes DNA Damage and Selective Inhibition of Topoisomerase IIα in Breast Cancer Cells
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone (Dp44mT) is being developed as an iron chelator with selective anticancer activity. We investigated the mechanism whereby Dp44mT kills breast cancer cells, both as a single agent and in combination with doxorubicin. Dp44mT alone induced selective cell killing in the breast cancer cell line MDA-MB-231 when compared with healthy mammary epithelial cells (MCF-12A). It induces G1 cell cycle arrest and reduces cancer cell clonogenic growth at nanomolar concentrations. Dp44mT, but not the iron chelator desferal, induces DNA double-strand breaks quantified as S139 phosphorylated histone foci (γ-H2AX) and Comet tails induced in MDA-MB-231 cells. Doxorubicin-induced cytotoxicity and DNA damage were both enhanced significantly in the presence of low concentrations of Dp44mT. The chelator caused selective poisoning of DNA topoisomerase IIα (top2α) as measured by an in vitro DNA cleavage assay and cellular topoisomerase-DNA complex formation. Heterozygous Nalm-6 top2α knockout cells (top2α+/−) were partially resistant to Dp44mT-induced cytotoxicity compared with isogenic top2α+/+ or top2β−/− cells. Specificity for top2α was confirmed using top2α and top2β small interfering RNA knockdown in HeLa cells. The results show that Dp44mT is cytotoxic to breast cancer cells, at least in part, due to selective inhibition of top2α. Thus, Dp44mT may serve as a mechanistically unique treatment for cancer due to its dual ability to chelate iron and inhibit top2α activity. [Cancer Res 2009;69(3):948–57]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATM and related protein kinases: safeguarding genome integrity
Shiloh, Y. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1011 · Cited by 2,577 · cited 12×
“We further investigated the molecular events associated with Dp44mT-induced cell cycle arrest by measuring the phosphorylation/activation of Chk1 and Chk2, which are known regulators of cell cycle checkpoints.”
BackgroundInfluentialThe DNA Damage Response: Ten Years After
Harper, J. W., & Elledge, S. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.015 · Cited by 1,705 · cited 1×
“The appearance of phosphorylated forms of both Chk1 and Chk2 is possibly indicative of their redundant effect for downstream inhibitory kinase activity on the Cdc25A phosphatase, which normally allows cellular progression through the G1-S phase (48).”
BackgroundThe role of iron regulatory proteins in mammalian iron homeostasis and disease
Rouault, T. A. (2006) · Nature Chemical Biology · doi:10.1038/nchembio807 · Cited by 1,055 · cited 1×
“The essential nature of elemental iron is evident in a multitude of cellular processes including proliferation, DNA synthesis, mitochondrial electron transport, and oxygen sensing (3, 4).”
BackgroundRegulation of iron acquisition and storage: consequences for iron-linked disorders
De Domenico, I., McVey Ward, D., & Kaplan, J. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2295 · Cited by 464 · cited 1×
“The essential nature of elemental iron is evident in a multitude of cellular processes including proliferation, DNA synthesis, mitochondrial electron transport, and oxygen sensing (3, 4).”
BackgroundTransferrin and transferrin receptors in carcinoma of the breast
Page Faulk, W., Hsi, B.-L., & Stevens, P. J. (1980) · The Lancet · doi:10.1016/s0140-6736(80)90440-7 · Cited by 280
Chelators at the cancer coalface: Desferrioxamine to Triapine and beyond
Yu, Y., Wong, J., Lovejoy, D. B., Kalinowski, D. S., & Richardson, D. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1954 · Cited by 195 · cited 1×
“goal of iron chelation therapy is to use it in conjunction with other chemotherapy drugs to limit the toxic side effects of drugs that induce reactive oxygen species, as occurs in heart tissue exposed to anthracycline drugs such as doxorubicin (45).”
Background
Cited by
Advances in Copper Complexes as Anticancer Agents
Santini, C., Pellei, M., Gandin, V., Porchia, M., Tisato, F., & Marzano, C. (2014) · Chemical Reviews · doi:10.1021/cr400135x · Cited by 1,790
Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities
Wondrak, G. T. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2541 · Cited by 462
Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis
Pinnix, Z. K., Miller, L. D., Wang, W., D’Agostino, R., Kute, T., Willingham, M. C., Hatcher, H., Tesfay, L., Sui, G., Di, X., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001127 · Cited by 448
Yu, Y., Kalinowski, D. S., Kovacevic, Z., Siafakas, A. R., Jansson, P. J., Stefani, C., Lovejoy, D. B., Sharpe, P. C., Bernhardt, P. V., & Richardson, D. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900552r · Cited by 397
Lovejoy, D. B., Jansson, P. J., Brunk, U. T., Wong, J., Ponka, P., & Richardson, D. R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1218 · Cited by 308
Metadata
- Authors
- Rao, V. A., Klein, S. R., Agama, K. K., Toyoda, E., Adachi, N., Pommier, Y., & Shacter, E. B.
- Venue
- Cancer Research
- Published
- 2009-01-29
- Volume
- 69
- Issue
- 3
- Pages
- 948-957
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2123968600
- Cited by
- 154
- References
- 6
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Iron Chelator Dp44mT Causes DNA Damage and Selective Inhibition of Topoisomerase IIα in Breast Cancer Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-1437
- The paper
- Rao, V. A., Klein, S. R., Agama, K. K., Toyoda, E., Adachi, N., Pommier, Y., & Shacter, E. B. (2009). The Iron Chelator Dp44mT Causes DNA Damage and Selective Inhibition of Topoisomerase IIα in Breast Cancer Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-1437
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.